tradingkey.logo
tradingkey.logo
Search

Transmedics Group Inc

TMDX
Add to Watchlist
87.000USD
-1.070-1.21%
Close 09-23 16:00ET
3.01BMarket Cap
17.24P/E TTM

Transmedics Group Inc (TMDX) Revenue Performance

Updated: Jun 30, 2026

Last year, Transmedics Group Inc generated 460.53M USD for its biggest-performing segment, OCS Liver net revenue. The United States made the largest contribution, accounting for 584.70M USD last year. For the latest quarter, Transmedics Group Inc reported the revenue of 148.23M USD for the period ending 2026-06-30, which came from the top-performing segment, OCS Liver net revenue. United States contributed the highest revenue, at 183.62M USD.

By Business

Annual
Annual
Quarterly
OCS Liver net revenue
OCS Heart net revenue
OCS Lung net revenue
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
OCS Liver net revenue
460.53M(76.58%)
309.62M(70.83%)
151.82M(64.13%)
46.26M(49.50%)
1.91M(6.32%)
5.25M(20.47%)
3.50M(14.82%)
OCS Heart net revenue
126.01M(20.95%)
109.86M(25.13%)
73.09M(30.88%)
38.35M(41.04%)
17.68M(58.43%)
14.20M(55.37%)
11.44M(48.47%)
OCS Lung net revenue
14.86M(2.47%)
17.68M(4.04%)
11.82M(4.99%)
8.85M(9.47%)
10.66M(35.24%)
6.19M(24.16%)
8.66M(36.71%)

By Region

Annual
Annual
Quarterly
United States
All other countries
United Kingdom
Germany
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
United States
584.70M(97.22%)
421.88M(96.50%)
221.35M(93.50%)
84.04M(89.92%)
21.86M(72.24%)
19.24M(75.04%)
16.25M(68.86%)
6.54M(50.27%)
2.74M(35.71%)
3.47M(55.85%)
All other countries
16.70M(2.78%)
15.28M(3.50%)
15.39M(6.50%)
9.42M(10.08%)
8.40M(27.76%)
6.40M(24.96%)
3.97M(16.82%)
2.44M(18.73%)
2.59M(33.66%)
1.39M(22.37%)
United Kingdom
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
2.23M(9.46%)
2.58M(19.82%)
2.35M(30.63%)
1.35M(21.77%)
Germany
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
1.15M(4.86%)
1.46M(11.19%)
--(--)
--(--)
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.